- Report
- October 2026
- 160 Pages
Global
From €3102EUR$3,320USD£2,592GBP
€3878EUR$4,150USD£3,239GBP
- Report
- February 2026
- 250 Pages
Global
From €4195EUR$4,490USD£3,505GBP
- Report
- August 2026
- 250 Pages
Global
From €4195EUR$4,490USD£3,505GBP
- Report
- January 2026
- 185 Pages
Global
From €4205EUR$4,500USD£3,513GBP
- Report
- July 2026
- 224 Pages
Global
From €7466EUR$7,990USD£6,237GBP
- Report
- July 2026
- 140 Pages
Global
From €7466EUR$7,990USD£6,237GBP
- Report
- July 2026
- 180 Pages
Global
From €4438EUR$4,750USD£3,708GBP
- Report
- June 2020
- 753 Pages
Global
From €3084EUR$3,300USD£2,576GBP
- Report
- August 2025
- 192 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Report
- August 2025
- 192 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Clinical Trials
- April 2025
- 115 Pages
Global
From €1869EUR$2,000USD£1,561GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1402EUR$1,500USD£1,171GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2606EUR$2,789USD£2,177GBP
- Report
- May 2024
- 134 Pages
Global
From €3737EUR$3,999USD£3,122GBP
- Report
- July 2021
- 50 Pages
China
From €2429EUR$2,600USD£2,030GBP
- Report
- November 2026
- 50 Pages
Global
From €2476EUR$2,650USD£2,069GBP

Temozolomide is an alkylating agent used in the treatment of certain types of cancer, most notably glioblastoma multiforme. It is a prodrug, which is converted in the body to its active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). Temozolomide is used in combination with radiation therapy to treat newly diagnosed glioblastoma multiforme, and as a single agent to treat recurrent glioblastoma multiforme. It is also used to treat anaplastic astrocytoma, a type of brain tumor.
Temozolomide is a generic drug, and is available in many countries. It is marketed by several companies, including Merck, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more